Target Volume Determination 2015

Results

Prostate carcinoma: T2

Prostate carcinoma: DCE-MRI

Author

n

Method Spec [%] Sens [%]

Scheidler J 1999

52

77 - 81

41 - 61

T2

80 68 87 63

70 82 88 80 87 74 75

MRS

Ito H 2003

111

dyn. MRI, peripheral

dyn. MRI, central

Review Müller-Lisse U 2003

T2 + MRS

Yuen JS 2004

24

57 57

T2

MRS

100

T2+ or MRS+

Prostate carcinoma: DWI

FDG-PET • T-Staging: Detection • Sensitivity localized disease 67% advanced disease92% • Limitations – Low glucose uptake – Large overlap between tumor and benign hyperplasia – Renal excretion of FDG into the bladder

Choline PET

• Better than FDG-PET • Still overlap between tumor and benign hyperplasia • N-Staging – Sensitivity 80%, – Specificity 96% – CT+MRI: Sensitivity 47%, specificity 98%

Grosu A, Strahlenther Onkol 2005